Avesthagen’s biopharmaceuticals business develops a comprehensive range of cost-effective biosimilars and antibody therapeutics for which the patent protection of the originator is either not valid for India and certain developing markets or is expected to expire.
Our current pipeline comprises of 8 biosimilar molecules. Two of which are in advanced stages of development with patents, processes, manufacturing rights for global licensing and sales & marketing.
■ AVDESP™: Biosimilar version of Darbepoetinalfa developed by Amgen Inc. Pre-clinical and efficacy studies for this molecule have been completed after obtaining the necessary approvals.
■ AVENT™: Biosimilar version of Etanercept, which targets autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis and psoriasis.
This portfolio is the subject of a current B2B licensing programme with Indian and global Pharma companies.The pharmaceuticals market in India is estimated to be c.$55 billion by 2020, representing a CAGR of over 22% according to a GlobalData study. One of the main drivers of India’s pharmaceutical sector is the biosimilars market, which is expected to increase to c.$40 billion globally by 2020 driven by the onset of biologic treatments introduced for diseases such as diabetes, cancer, multiple sclerosis, and rheumatoid arthritis. Lower cost manufacturing, less expenditure incurred on research and development and a higher number of drug applications and approvals mean that together India and China are expected to command around 70% of the global biosimilars market by 2020.